πŸ‡ΊπŸ‡Έ

US SEC Filing Intelligence

Β· daily

US Executive Officer Management Changes SEC β€” March 17, 2026

Across 44 SEC filings on US executive and director changes from March 17, 2026, a net positive shift emerges with 22 appointments/promotions (51%) outpacing 20 resignations/retirements (45%), predominantly neutral but tilted positive in healthcare/biotech/tech sectors via high-caliber hires like ex-Air Force official at Redwire and Stryker CEO at GE HealthCare. Period-over-period trends in enriched data show robust revenue acceleration in biotechs (Bicycle Therapeutics +94% YoY Q4 collab rev to $48M, Neuronetics +86% YoY Q4 to $41.8M, +99% FY to $149.2M) but margin compression (Neuronetics gross margin -2370 bps YoY to 48.5%) and net losses widening (Bicycle FY -219M vs -169M). Critical developments include clustered resignations by Susan B. McGee from 6+ Goldman-related entities (filings 20-24,44), signaling potential portfolio consolidation, and Gran Tierra's 4-director exodus over audit disputes (filing 31). Capital allocation highlights include First Industrial's new $250M buyback (filing 3) and equity grants/RSUs across Coursera, Hinge Health, NWPX (filings 16,11,43). Forward-looking catalysts feature Neuronetics FY2026 rev guidance $160-166M, Cencora reaffirmed FY2026 adj EPS $17.45-17.75, and multiple AGMs Q2 2026. Portfolio implications: Favor firms with strategic hires amid transitions; monitor governance risks in energy/financials for volatility.

44 high priority 44 total filings
Β· daily

US Corporate Distress Financial Stress SEC Filings β€” March 17, 2026

Across 42 filings in the USA Corporate Distress & Bankruptcy stream, dominant themes include aggressive liquidity maneuvers via high-cost convertible notes, equity offerings, and debt restructurings (e.g., 10+ issuances of notes/preferred with 15-22% effective rates), Nasdaq compliance failures (4 cases with delisting/reverse split risks), and covenant amendments signaling near-term stress, amid limited explicit YoY/QoQ data but clear patterns of debt settlements reducing burdens (e.g., Integrated Rail settled $705k, i-80 Gold retired $165M). Positive offsets feature major contracts (Duos $176M over 36 months), grants (Clene $8M), and M&A (Public Storage acquiring NSA), with sentiments skewing positive/neutral in 70% of cases despite distress focus. Critical developments like Urgent.ly's imminent delisting and New Fortress Energy's RSA (diluting shareholders to 35%) heighten bankruptcy risks, while refinancings (Indivior $500M at 0.625%, Beazer +43.8% facility) provide relief. Portfolio-level: Small-cap biotechs/tech show repeated dilution/equity raises (12 cases), airlines/construction deferrals indicate capex cuts, no broad margin compression trends evident but liquidity covenants relaxed in 3 filings. Implications: Heightened short opportunities in non-compliant names, long setups in turnaround financings with catalysts.

42 high priority 42 total filings
Β· daily

US SEC Trading Suspension Halt Orders β€” March 17, 2026

Nasdaq listing compliance challenges dominate the USA Trading Suspensions stream, with Urgent.ly Inc. facing trading suspension on March 18, 2026, and delisting due to failure to meet net income requirements under Rule 5550(b) by the March 16 deadline, despite a March 13 merger agreement with Agero. Fractyl Health received a bid price deficiency notice under Rule 5450(a)(1) on March 13, with 180 days to cure by September 9, 2026, highlighting ongoing liquidity risks for small caps. In contrast, Incannex Healthcare cured its prior bid price deficiency under Rule 5550(a)(2) as of March 16, maintaining $1.00+ closes for 11 consecutive business days from February 27 to March 13, resolving overhangs from 2025 filings. No explicit period-over-period financial trends across filings, but Incannex outperforms with $75M cash, zero debt, and positive Phase 2 clinical data versus peers' regulatory distress. Mixed sentiment overall (1 positive, 1 negative, 1 mixed), with healthcare names (Fractyl, Incannex) showing bid price volatility patterns. Portfolio implications include heightened delisting risks reducing trading volumes, potential OTC transitions, and merger catalysts as offsets. Actionable theme: monitor tender offers and compliance deadlines for short-term trading opportunities.

3 high priority 3 total filings
Β· daily

US Corporate Board Director Changes SEC Filings β€” March 17, 2026

Across 44 SEC filings on USA Board Room Changes dated March 17, 2026, the dominant theme is extensive board and executive reshuffles, with 22 appointments/promotions (e.g., new directors/CEOs/CFOs) versus 20 resignations/retirements, 80% neutral sentiment but positive tilt from high-profile adds in healthcare/tech (e.g., Redwire, GE HealthCare, Neuronetics). Period-over-period trends in disclosed financials show robust revenue growth in biotechs (Bicycle Therapeutics +37.3% FY YoY to $72.6M, Neuronetics +99% FY to $149.2M) but margin compression (Neuronetics gross margin -2370 bps to 48.5%) and mixed net losses. No widespread insider selling detected, but capital allocation shines with First Industrial's new $250M buyback (no expiration) and DLH's equity plan expansion approved. Healthcare/biotech leads with 12 changes signaling stabilization amid R&D/cash runway extensions to 2030; energy flags risks from Gran Tierra's 4-director exodus over audit disputes. Portfolio implication: monitor succession risks in mature firms (e.g., Cencora CFO retire June 2026) versus growth refreshes offering alpha.

44 high priority 44 total filings
Β· daily

US Merger & Acquisition SEC Filings β€” March 17, 2026

The 15 filings reveal a robust wave of M&A and takeover activity dominated by SPAC/deSPAC transactions (9/15 filings), with amendments, financings, and adjournments signaling persistent deal-making amid delays. Completed mega-deals include Alexander & Baldwin's $2.3B take-private at $21.20/share, IBM's $11B acquisition of Confluent at $31/share, and Fulgent's $56.9M asset buys, highlighting strong buyer appetite in real estate, tech/AI, and diagnostics. Positive sentiment prevails (8/15 positive, 4 neutral, 3 mixed), with no reported period-over-period financial declines or metric compressions across filings; instead, forward-looking catalysts like Q2 2026 revenue ramps and IND submissions dominate. SPAC extensions (e.g., Israel Acq to Apr 15) and bridge notes indicate capital raises to bridge to closings, while fresh IPOs like GalaxyEdge's $115M raise underscore new liquidity. Portfolio-level pattern: 6/15 filings involve procedural advances (amendments/adjournments) without financial revisions, suggesting stable valuations but timing risks. Overall, bullish M&A momentum implies sector rotation opportunities into targets and acquirers, with catalysts clustered in late March.

15 high priority 15 total filings
Β· monthly

US Pre-Market SEC Filings Roundup β€” March 17, 2026

Overnight SEC filings from March 16-17, 2026 reveal mixed financial performance across sectors, with standout YoY revenue growth in select names like Mechanics Bancorp (+817% net income post-merger), Ethos Technologies (+52% revenue), and PURE Bioscience (+21.7% six-month revenue), contrasted by margin compressions in Dragonfly Energy (-250 bps gross margin QoQ) and Xerox Holdings (-440 bps total gross margin). SPAC and M&A activity dominates with positive sentiment around AParadise/Enhanced Games merger ($1.3B valuation), Pelican/Greenland energy deSPAC, and Two Harbors/UWM acquisition push, while activist pressure mounts at Lululemon via Dennis Wilson's 8.4% stake and board criticism. Capital allocation trends favor buybacks (First Industrial $250M program) and debt settlements (Integrated Rail), but dilutive financings (American Rebel 15% effective note, Hammer related-party loans) raise dilution risks. Forward-looking catalysts include BioCardia FDA pre-submission acceptance, Dragonfly Q1 2026 guidance ($9.5M sales, -$4.6M Adj EBITDA), and multiple proxy meetings (Carlisle April 29). Routine ABS servicing compliance in 10+ 10-Ks signals stable RMBS/ABS operations with no material issues. Portfolio-level, 7/15 high-materiality filers show revenue growth averaging +25% YoY but mixed profitability, favoring opportunistic plays in SPACs and post-merger banks amid pre-market positioning.

39 high priority 11 medium 50 total filings
Β· daily

S&P 500 Consumer Staples Sector SEC Filings β€” March 16, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (with broader cross-sector context), dominant themes include steady capital returns via dividends (Benchmark $0.17/shr, Pebblebrook $0.01 common + prefs, Coca-Cola resilient outlook), frequent leadership transitions signaling strategic shifts (KORU CEO retirement 6/30/26, Helmerich CFO 6/30/26, Coca-Cola CEO to Henrique Braun), and mixed financials with revenue acceleration in 8/18 reporting companies averaging +32% YoY (Telos +52%, Gilat +48%, OPAL +16%) offset by margin compression in 7/12 cases averaging -380bps (Gilat -700bps, Dell products -210bps). Period-over-period trends reveal improving cash flows in turnarounds (Telos op CF +$56.1M to $30.2M, Comtech H1 +$34.9M to $12.9M) but widening losses in 6/15 small caps (KEEMO -62% worse, FutureFuel rev -61%). Forward-looking catalysts cluster in Q2-Q3 2026 (DuPont aramids sale 4/1, Black Diamond GBM trial Q2, Rafael topline Q3), with OPAL's 2026 EBITDA guidance $95-110M as a growth beacon. Portfolio implications favor selective longs in high-growth outliers like OPAL/Telos amid sector volatility, with watch for M&A closes and trial readouts driving alpha.

28 high priority 22 medium 50 total filings
Β· daily

S&P 500 Industrials Sector SEC Filings β€” March 16, 2026

Across 50 filings in the USA S&P 500 Industrials stream, key themes include robust revenue acceleration in power/infrastructure plays like Forgent Power Solutions (+69% YoY to $296M Q2, bookings +268%) and WaterBridge (+66% YoY to $525.6M FY25), offset by volume pressures in defense (SAIC -5% YoY Q4) and machinery (Comtech -16% YoY Q2 sales). Aggregate period trends: 8/15 revenue-reporting firms showed +20%+ YoY growth (avg +55%), but 6/10 reported net losses or widened due to one-offs, impairments, and debt costs; margins resilient in 4 cases (Comtech +720bps, SAIC +20bps FY). Capital allocation bullish with $422M SAIC buybacks, Amphastar +$50M program, multiple dividend hikes/initiations (ServisFirst $0.38, WaterBridge $0.05). M&A active: Public Storage-NSA merger (multiple filings), Addentax Keemo acquisition. Banks exhibit NI surges (+45% PCB, +49% Orange County) but rising NPAs/NPLs (+69% PCB nonaccruals, +76% Orange NPLs). Forward-looking signals mixed: Forgent +73% FY26 guide vs SAIC -4-2% organic; catalysts cluster Mar-Apr AGMs/earnings and Q2 2026 BLAs. Actionable: overweight infra growth, monitor credit deterioration.

25 high priority 25 medium 50 total filings
Β· daily

S&P 500 Energy Sector SEC Filings β€” March 16, 2026

Across the 8 S&P 500 Energy stream filings (with some industrial/biotech outliers), key themes include robust revenue growth in 5/8 companies (e.g., Ampco-Pittsburgh +4% YoY FY sales to $434.2M, Stoke +404% YoY to $184M) offset by one-time losses and margin pressures, exemplified by Ampco's Q4 Adjusted EBITDA -47% YoY to $3.2M and FY operating loss of $(54.5M). Energy pure-plays shine: Marathon Petroleum (MPC) reported $4.0B 2025 net income, $12.0B adjusted EBITDA, 94% refining utilization, and $4.5B shareholder returns including 10% dividend hike to $1.00/share, while Dorchester Minerals secured $15.5M litigation settlement boosting April 2026 distributions. Capital allocation leans shareholder-friendly in energy (MPC $4.4B buyback authorization remaining), with forward-looking uplift from Ampco's UK facility exit ($7-8M annual EBITDA). Proxies signal routine governance (MPC DEFA14A/DEF14A, Peapack), but mixed sentiment prevails in 3/8 filings due to charges/backlog declines. Portfolio implications: Favor MPC/Dorchester for near-term yields; monitor Ampco/Stoke turnarounds amid Q4 weakness. Catalyst-rich: Earnings calls and AGMs in March-April 2026.

5 high priority 3 medium 8 total filings
Β· daily

S&P 500 Financials Sector SEC Filings β€” March 16, 2026

Across 50 filings from S&P 500 Financials and related streams, overarching themes include mixed financial performance with revenue declines averaging -7% YoY in 14/25 reporting companies (e.g., Townsquare -5.2%, iQIYI -6.6%, LivePerson -22%) offset by aggressive cost reductions boosting operating income (e.g., Townsquare +103.8%) and EBITDA (WaterBridge +68% to $254M); notable M&A and capital markets activity like Kennedy-Wilson merger amendments requiring 2/3 vote excl. insiders, Armada Hoffler $562M asset sale, and MSC Income $150M notes. Fintech standouts like Figure Technology (+48.7% rev to $507M, +574% NI) and Blend Labs (+7% rev, op cash flow positive $14.4M) contrast with bank/insurer stability (PCB Bancorp +45% NI, AIG director exit neutral). Capital allocation favors buybacks (Amphastar +$50M) and dividends (Townsquare $0.20 qtrly, PCB +11%), while SPACs extend deadlines amid redemptions (Trailblazer to June 2026). Forward guidance mixed but growth-oriented (Townsquare FY2026 $420-440M rev, WaterBridge +7-9% EBITDA), signaling portfolio-level resilience amid sector rotation opportunities. Implications: Favor fintech/bank growth outliers, monitor merger votes and Q1 catalysts for alpha.

32 high priority 18 medium 50 total filings
Β· daily

US Material Events SEC 8-K Filings β€” March 16, 2026

Across 50 SEC filings from March 16, 2026, dominant themes include a surge in M&A activity (8 deals closed, amended, or announced, e.g., Quipt going private at $3.65/share, Interactive Strength acquiring Ergatta for $8.75M+ equity), widespread executive transitions (20+ resignations, appointments, retirements across CEOs, CFOs, directors), and debt refinancings/capital raises (12 issuances totaling >$25B, often extending maturities or funding growth). Period-over-period trends where reported show mixed results: Urgent.ly Q4 revenue +4% YoY (gross margin +400bps to 26%) but FY revenue -10% YoY; Dragonfly FY revenue +15.8% YoY (OEM +33.8%) but Q4 gross margin -260bps to 18.2% and net loss widened to $(69.9M). Capital allocation leans toward buybacks (Boston Beer $25M plan), executive equity grants (Victory $79.4M, Deere $35M), and deleveraging (Armada Hoffler $562M asset sale). Biotech/pharma outliers shine with positive financings (Alto $120M, Acumen $35.75M); real estate/financials focus on restructuring. Market implications: heightened M&A signals consolidation in small-caps, leadership churn may introduce volatility but signals continuity via interim appointments, debt activity supports liquidity amid higher rates.

50 high priority 50 total filings
Β· daily

S&P 500 Technology Sector SEC Filings β€” March 16, 2026

Across 14 SEC filings in the USA S&P 500 Technology stream, revenue declines dominate with 4 key reporters averaging -10.7% YoY (Townsquare -5.2%, Comtech Q2 -15.6%/H1 -10.2%), driven by broadcast/advertising weakness and product eliminations, but countered by margin expansions via cost cuts (Comtech gross margin +720bps to 33.9%, Adjusted EBITDA +214% to $9.1M; Townsquare op income +103.8%). Capital allocation trends bullish in software giants: Intuit accelerated buybacks +40% YoY to $1.8B H1 with $3.5B remaining after terminating 10b5-1 sales plans; Salesforce $25B ASR signals conviction. Digital shifts resilient (Townsquare digital +0.9% to 55% of rev), turnarounds evident (Nuvera NI +107.4% to $0.3M from $4.4M loss), but debt pressures persist (Townsquare leverage 5.19x, interest +32.3%). Mixed sentiment in 5/14 filings reflects operational resilience amid macro headwinds; backlog strength (Comtech $732M, +120.9% bookings) flags recovery potential. Guidance cautious (Townsquare FY26 rev $420-440M flat YoY), with catalysts like AParadise De-SPAC and May events. Portfolio implication: overweight buyback leaders (Intuit, Salesforce), monitor small-cap debt for downside.

8 high priority 6 medium 14 total filings
Β· daily

Nasdaq 100 Stocks SEC Filings β€” March 16, 2026

Across the 13 NASDAQ-100 related filings from March 16, 2026, key themes include margin expansion and profitability improvements despite revenue softness in select companies like Comtech (Q2 sales -15.6% YoY but gross margin +720 bps to 33.9%, Adjusted EBITDA +214% to $9.1M), contrasting with positive capital allocation signals such as Intuit's termination of 10b5-1 sales plans and acceleration of $3.5B share repurchases (H1 repurchases +40% YoY to $1.8B). Amazon's €14.5B Euro notes issuance at low coupons (2.8%-4.85%) signals strong access to cheap debt markets, while SPAC/IPO activity (Metals Acquisition $200M IPO, Madison Air S-1/A) highlights M&A momentum. Governance enhancements (CoStar's new AI-experienced director) and operational outperformance (AParadise's AOV +18%, subscription +25%) point to AI/data tailwinds, but debt pressures persist (Nuvera interest expense up, Comtech non-current debt +$7.9M to $103.5M). Portfolio-level trends show 3/5 detailed financial reporters with YoY profitability gains (e.g., Comtech H1 gross profit +51.3%, Nuvera net income +107.4% from loss), mixed revenue (2 declines averaging -13%), and bullish capital returns. Critical implications: Favor margin turnarounds and buyback accelerators amid soft revenue; monitor De-SPACs and reporting changes for catalysts.

8 high priority 5 medium 13 total filings
Β· daily

Dow Jones 30 Stocks SEC Filings β€” March 16, 2026

Across 50 SEC filings from Dow Jones 30-focused stream (Mar 16, 2026), key themes include resilient banking sector growth with net income up 45-49% YoY in PCB Bancorp/Orange County Bancorp amid NIM expansion, contrasted by revenue declines averaging -15% YoY in tech/defense firms like SAIC (-3% FY26), LivePerson (-22%), and Comtech (-15.6% Q2 FY26), though margins improved (e.g., Comtech gross margin +720bps to 33.9%). M&A activity surged with 6 deals (Interactive Strength/Ergatta $3.5M+$5-9.5M stock, Allison/Dana $2.73B, Zevra SDX sale $50M), leadership transitions in 10+ firms (Fortune Brands interim CEO, Baxter interim CFO), and capital returns via dividends/buybacks (SAIC $422M FY26 repurchases, ServisFirst $0.38/share). Mixed sentiment dominates (18/50), with forward guidance cautious (SAIC FY27 rev -4-2% organic) but clinical catalysts (Perspective VMT-Ξ±-NET mid-2026 data) and bank efficiency gains (PCB ROA 1.15% +). Portfolio implications: overweight banks for NIM tailwinds, monitor tech margin recovery vs rev weakness, position for M&A catalysts.

27 high priority 23 medium 50 total filings
Β· daily

US SEC Filings Daily Market Digest β€” March 16, 2026

Across 50 SEC filings for March 16, 2026, mixed FY2025 financials dominate with 12/20 10-Ks showing revenue declines averaging -10% YoY (e.g., Townsquare -5.2%, iQIYI -6.6%, LivePerson -22%) offset by outliers like Figure Technology +48.7% and WaterBridge +66%, while margins improved in 7/15 cases via cost cuts (e.g., Townsquare op income +103.8%). M&A and restructuring activity surges in real estate (Kennedy-Wilson amendment, Armada Hoffler $562M sale) and biotech/pharma (Alto Neuroscience pipeline, Urgent.ly merger), alongside capital returns like Amphastar $50M buyback increase and Townsquare $0.20 dividend maintenance. Management transitions signal continuity (CoStar AI expert director, KORU CEO succession), but risks loom from widening losses (Alto -3% YoY net loss) and leverage rises (WaterBridge borrowings +140% YoY). Sector pivots to AI/HPC (Mawson, CoStar) and positive guidance (Townsquare FY2026 $420-440M revenue) point to recovery potential, with portfolio-level trends favoring cost discipline amid soft revenue. Implications: Favor resilient growth names like PCB Bancorp (+45% net income) and Blend Labs (loss narrowing to $7M), monitor merger votes for catalysts.

31 high priority 19 medium 50 total filings
Β· daily

S&P 500 Consumer Discretionary Sector SEC Filings β€” March 16, 2026

Across the 50 filings in the USA S&P 500 Consumer Discretionary intelligence stream (despite diverse inclusions like infra/energy/crypto), mixed sentiment dominates with 18/50 showing mixed signals, driven by robust revenue growth in select names (e.g., Forgent Power +69% YoY Q2 rev to $296M, Figure Tech +48.7% FY25 to $507M) offset by declines (SFL Corp -19% rev to $733M, FutureFuel -61% to $95.7M). Period-over-period trends reveal YoY revenue acceleration in 15/50 companies averaging +40% where positive, but margin compression in 12/50 (avg -100bps) and net losses widening in 10/50 due to impairments/expenses. Capital allocation shines with dividends declared/initiated in 5 names (ServisFirst $0.38/shr, WaterBridge $0.05/shr quarterly) and buybacks noted (Truist $10B program, Marathon $4.5B returned). M&A momentum includes NSA/Public Storage merger (3 filings), Armada Hoffler $562M asset sale, and KEEMO control stake acquisition. Forward-looking guidance is bullish in infra/power (Forgent FY26 rev $1.275-1.325B +73%), with April 2026 AGMs (Ferguson, Truist, Marathon) as key catalysts. Crypto ETF index changes (Grayscale BTC/ETH, 5 filings) are neutral operational tweaks effective Apr 1. Portfolio implication: favor growth infra/consumer plays amid capex cycles, monitor M&A for consolidation.

28 high priority 22 medium 50 total filings
Β· daily

S&P 500 Healthcare Sector SEC Filings β€” March 16, 2026

In the USA S&P 500 Healthcare stream, biotech and medtech firms dominate with mixed but stabilizing financials: revenues grew in devices (Smith & Nephew +6.1% YoY) while core sales declined in nutritionals (USANA -8.3% YoY), and biotechs narrowed losses (Rallybio -84% net loss YoY, HeartSciences -4% 9mo) amid pipeline catalysts. Cash positions strengthened significantly (Alto +5% to $177M funding into 2028, HeartSciences +209% to $3.4M), supported by $120M Alto raise and operational efficiencies (Rallybio opex -44% YoY). Broader filings reveal robust capital returns (SAIC $422M FY26 buybacks, Truist $10B new program, $5.2B returned 2025) and proxy season peaks with 10+ April 2026 meetings. Forward-looking optimism in healthcare via Alto's 1Q26/1H26 data/trials, Moderna's 8 oncology programs, Smith & Nephew's 6-7% CAGR RISE plan to 2028. Portfolio trends: 5/8 key HC firms improved cash/equity YoY, but margins compressed avg -150bps in 3/8 (USANA -370bps op); non-HC financials showed net income growth avg +25% YoY (SMARTFinancial +39%). Critical implications: Biotech catalysts cluster 1H26, signaling alpha in small/mid caps; monitor dilution from raises and weak bookings (SAIC Q4 btb 0.3x).

30 high priority 20 medium 50 total filings
Β· daily

Global High-Priority Regulatory Events β€” March 16, 2026

Across 50 filings in the 'Global High Priority Market Events' stream (US SEC focus, March 16, 2026), dominant themes include a surge in M&A/takeovers (9 filings: Interactive Strength-Ergatta close, Axalta-AkzoNobel merger, Urgent.ly-Agero acquisition), SPAC/de-SPAC extensions/promotions (Xanadu, FACT II, Trailblazer), and financial distress in Indian firms (MTNL defaults β‚Ή2,096 Cr overdue, Quadrant CIRP extension to May 30, 2026). Period-over-period trends show mixed revenue performance (avg -5% YoY in media/tech like Townsquare -5.2%, iQIYI -6.6%; +30-50% in select fintech/energy like Figure Tech +48.7%, WaterBridge +66%), with net losses narrowing in 6/15 reporting cos (e.g., Blend Labs -84% YoY to $7M, Urgent.ly Q4 op loss -46%) but widening in biotechs/distressed (Alto +3%, Vanguard +62-125%). Capital allocation leans defensive (Airbnb $2.5B debt refinance to 2029-2036 despite +4.4-5.25% rates; PCB dividends +11% to $0.80/share), while forward-looking catalysts cluster in H2 2026 (merger closes, proxy votes). Portfolio-level patterns flag Indian insolvency risks (3/50 negative sentiment), US M&A bullishness (positive in 70% deals), and SPAC liquidity pressures (redemptions driving trust declines). Critical implications: Opportunistic M&A in tech/defense, avoid Indian telecom distress, monitor SPAC extensions for dilution.

50 high priority 50 total filings
Β· daily

US IPO Pipeline SEC S-1 Filings β€” March 16, 2026

The IPO Pipeline stream saw limited but material activity on March 16, 2026, with two filings: MasterCraft Boat Holdings' S-4 registering shares for its February 5, 2026 merger with Marine Products, and Presidio Production Co's S-1 advancing its post-SPAC IPO in crude oil/gas production. MasterCraft's pro forma financials reveal combined net sales of $509M for YE June 30, 2025 (up from implied historical segments) but sharp income decline to $10M from historical ~$25M sum (~60% drop due to $65M goodwill, $62M intangibles amortization, and expenses), signaling earnings dilution post-merger. Presidio's filing incorporates recent March 4, 2026 credit agreement and December 31, 2025 reserve reports, with no metrics provided but neutral sentiment amid governance updates post-August 2025 SPAC merger. Cross-filing trends show pro forma balance sheet strength (MasterCraft assets $436M, equity $343M) contrasting absent financials in Presidio, highlighting marine sector consolidation versus energy de-SPAC momentum. Market implications include potential boating market share gains for MasterCraft amid cyclical recovery, while Presidio adds to oil/gas public supply; overall quiet session underscores selective IPO/M&A pipelines in niche sectors.

2 high priority 2 total filings
Β· daily

US Earnings Financial Results SEC Filings β€” March 16, 2026

Across 50 US SEC filings for Q4 2025/FY2025 earnings (filed ~March 16, 2026), mixed sentiment prevails in 80% of cases, with biotechs/pharmas (20+ firms) showing widened net losses averaging +30% YoY from R&D spikes but offset by $200M+ aggregate equity raises (e.g., Olema $205M, Zenas via licenses); banks (PCB, Orange County, Embassy) delivered +45% avg net income growth on NIM expansion to ~4% but NPAs rose 50-70% YoY signaling credit stress. Tech/software leaders like Samsara (+30% rev, 77% margins), Dell (+19% rev, $11B op cash flow), Figure (+49% rev) drove positive outliers vs sector drags (LivePerson -22% rev); energy firms mixed with NGS rentals +14% horsepower but Aemetis volumes -7-72%. Portfolio trends: Revenue +10% avg in top 20 performers, cost cuts yielded EBITDA gains in 65% (avg +50%), but cash burns persist in pre-revenue (Eve $224M loss); capital returns via bank dividends (+11% yields) and Dell $1B+ buybacks. Critical: Rising impairments/debt in 40%, but 15 firms flipped to EBITDA positive, implying turnaround alpha in cost-disciplined growth names amid macro caution.

50 high priority 50 total filings